Current Treatment Options in Oncology

, Volume 8, Issue 6, pp 402–416 | Cite as

Quality-of-Life Issues in the Management of Epithelial Ovarian Cancer

  • Thomas Lowe
  • Betty FerrellEmail author
  • Lucille Leong
Gynecologic Tumors

Opinion statement

The importance of quality-of-life (QOL) measurements in cancer management is being increasingly appreciated. This is especially important in patients with advanced cancers. Over 80% of women with epithelial ovarian cancer (EOC) will present with disease outside the ovary as there are no accurate screening tests, and symptoms usually do not develop until EOC has spread. Standard treatment includes debulking surgery followed by chemotherapy to which most women will have a complete response but only a minority of women with advanced disease will be cured. Fortunately, advances in surgical and chemotherapeutic management have improved overall survival with 45% of women of all stages living 5 years or longer. EOC may in many cases be considered a “chronic cancer,” which highlights the importance of QOL in management decisions. QOL may be affected by the disease itself as well as by surgical and chemotherapeutic treatments. Future studies of the care and treatment of EOC patients should include well-designed QOL evaluations.


Ovarian Cancer Paclitaxel Clin Oncol Epithelial Ovarian Cancer Gynecologic Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

Papers of particular interest have been highlighted as: •Of importance ••Of major importance

  1. 1.
    Jemal A, Siegel R, Ward E, et al.: Cancer statistics 2007. CA Cancer J Clin 2007, 57:43–66CrossRefPubMedGoogle Scholar
  2. 2.
    Morgan RJ Jr, Alvarez RD, Armstrong DK, et al.: Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4:912–939PubMedGoogle Scholar
  3. 3.••
    Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34–43CrossRefPubMedGoogle Scholar

Third and most recent large phase III randomized study showing superiority of combination IV and IP chemotherapy over IV chemotherapy alone.

  1. 4.
    Lowe T, Morgan RJ Jr: Intraperitoneal chemotherapy in ovarian cancer. Future Med-Women’s Health 2007, 3:433–440Google Scholar
  2. 5.
    Cannistra SA: Cancer of the ovary. N Engl J Med 2004, 351:2519–2529CrossRefPubMedGoogle Scholar
  3. 6.
    Ferrell BR, Dow KH, Grant M: Measurement of the quality of life in cancer survivors. Qual Life Res 1995, 4:523–531CrossRefPubMedGoogle Scholar
  4. 7.••
    Ferrell B, Smith SL, Cullinane CA, Melancon C: Psychological well being and quality of life in ovarian cancer survivors. Cancer 2003, 98:1061–1071CrossRefPubMedGoogle Scholar

Qualitative data analysis from more than 21,806 items of␣natural correspondence over 7 years between EOC survivors and an ovarian cancer newsletter-“Conversations-The International Newsletter for those Fighting Ovarian Cancer”

  1. 8.
    Penson RT, Wenzel LB, Vergote I, Cella D: Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95:S247–S257CrossRefPubMedGoogle Scholar
  2. 9.
    Bottomley A: The cancer patient and quality of life. Oncologist 2002, 7:120–125CrossRefPubMedGoogle Scholar
  3. 10.
    Sanders C, Egger M, Donovan J, et al.: Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998, 317:1191–1194PubMedGoogle Scholar
  4. 11.
    Kornblith AB, Thaler HT, Wong G, et al.: Quality of life of women with ovarian cancer. Gynecol Oncol 1995, 59:231–242CrossRefPubMedGoogle Scholar
  5. 12.
    Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al.: Quality of life of women with ovarian cancer. Gynecol Oncol 1995, 59:231–242CrossRefGoogle Scholar
  6. 13.
    Wenzel LB, Donnelly JP, Fowler JM, et al.: Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 2002, 11:142–153CrossRefPubMedGoogle Scholar
  7. 14.
    Norton TR, Manne SL, Rubin S, et al.: Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol 2004, 22:919–926CrossRefPubMedGoogle Scholar
  8. 15.
    Efficace F, Osoba D, Gotay C, et al.: Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 2007, 18:775–781CrossRefPubMedGoogle Scholar
  9. 16.
    Joly F, Vardy J, Pintilie M, Tannock I: Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 2007, Aug 13 [Epub ahead of print]Google Scholar
  10. 17.
    Cella DF, Tulsky DS, Gray G: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570–579PubMedGoogle Scholar
  11. 18.
    Butler L, Bacon M, Carey M, et al.: Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 2004, 22:2461–2468CrossRefPubMedGoogle Scholar
  12. 19.
    Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al.: Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001, 19:1809–1817PubMedGoogle Scholar
  13. 20.
    Fitch M, Gray RE, Franssen E: Perspectives on living with ovarian cancer: young women’s views. Can Oncol Nurs J 2000, 10:101–108PubMedGoogle Scholar
  14. 21.
    Aletti GD, Dowdy SC, Gostout BS, et al.: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006, 107:77–85PubMedGoogle Scholar
  15. 22.
    Fader AN, Rose PG: Role of surgery in ovarian carcinoma. J Clin Oncol 2007, 25:2873–2883CrossRefPubMedGoogle Scholar
  16. 23.
    Panici PB, Maggioni A, Hacker N, et al.: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005, 97:560–566PubMedGoogle Scholar
  17. 24.
    Maggioni A, Benedetti Panici P, Dell’Anna T, et al.: Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006, 95:699–704CrossRefPubMedGoogle Scholar
  18. 25.
    Crawford SC, Vasey PA, Paul J, et al.: Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 2005, 23:8802–8811CrossRefPubMedGoogle Scholar
  19. 26.
    Schilder JM, Thompson AM, DePriest PD, et al.: Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002, 87:1–7CrossRefPubMedGoogle Scholar
  20. 27.
    Colombo N, Parma G, Lapresa MT, et al.: Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer 2005, 15:206–211CrossRefPubMedGoogle Scholar
  21. 28.
    Schlaerth AC, Abu-Rustum NR: Role of minimally invasive surgery in gynecologic cancers. Oncologist 2006, 11:895–901CrossRefPubMedGoogle Scholar
  22. 29.
    Ozols RF, Fisher RI, Anderson T, et al.: Peritoneoscopy in the management of ovarian cancer. Am J Obstet Gynecol 1981, 140:611–619PubMedGoogle Scholar
  23. 30.
    van der Burg ME, van Lent M, Buyse M, et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the European organization for research and treatment of cancer. N Engl J Med 1995, 332:629–634CrossRefPubMedGoogle Scholar
  24. 31.
    Redman CW, Warwick J, Luesley DM, et al.: Intervention debulking surgery in advanced epithelial ovarian cancer. Brit J Obstet Gynaecol 1994, 101:142–146Google Scholar
  25. 32.
    Rose PG, Nerenstone S, Brady MF, et al.: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004, 351:2489–2497CrossRefPubMedGoogle Scholar
  26. 33.
    Wenzel L, Huang HQ, Monk BJ, et al.: Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2005, 23:5605–5612CrossRefPubMedGoogle Scholar
  27. 34.
    Kumar L, Hariprasad R, Kumar S, et al.: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): a prospective randomized study—Interim results [abstract]. Proc ASCO 2007, 25:5531.
  28. 35.•
    Alberts DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996, 335:1950–1955CrossRefPubMedGoogle Scholar

First large randomized phase III study of intraperitoneal chemotherapy.

  1. 36.•
    Markman M, Bundy BN, Alberts DS, et al.: Phase III trial of standard-dose intravenous Cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol 2001, 19:1001–1007PubMedGoogle Scholar

Second large randomized phase III study of intraperitoneal chemotherapy.

  1. 37.
    Kyrgiou M, Salanti G, Pavlidis N, et al.: Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 2006, 98:1655–1663PubMedGoogle Scholar
  2. 38.
    Bezjak A, Tu D, Bacon M, et al.: Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 2004, 22:4595–4603CrossRefPubMedGoogle Scholar
  3. 39.
    Neijt JP, Engelholm SA, Tuxen MK, et al.: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000, 18:3084–3092PubMedGoogle Scholar
  4. 40.•
    Ozols RF, Bundy BN, Greer BE, et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194–3200CrossRefPubMedGoogle Scholar

Established carboplatin and paclitaxel as standard of care for primary postoperative therapy for EOC.

  1. 41.•
    du Bois A, Lück HJ, Meier W, et al.: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320–1329PubMedGoogle Scholar

Established carboplatin and paclitaxel as standard of care for primary postoperative therapy for EOC.

  1. 42.
    Greimel ER, Bjelic-Radisic V, Pfisterer J, et al.: Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 2006, 24:579–586CrossRefPubMedGoogle Scholar
  2. 43.•
    Vasey PA, Jayson GC, Gordon A, et al.: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96:1682–1691PubMedCrossRefGoogle Scholar

Randomized phase III study comparing docetaxel versus paclitaxel in combination with carboplatin. Global QOL was similar many symptom scores favored docetaxel. The current primary postoperative chemotherapy recommendation is for paclitaxel or docetaxel in combination with carboplatin.

  1. 44.
    Wenzel LB, Huang HQ, Armstrong DK, et al.: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:437–443CrossRefPubMedGoogle Scholar
  2. 45.
    Wenzel LB, Huang HQ, Armstrong DK, et al.: Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study [abstract]. Proc ASCO 2006, 24:5007.
  3. 46.
    Sun CC, Ramirez PT, Bodurka DC: Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 2007, 4:18–29CrossRefPubMedGoogle Scholar
  4. 47.
    Sun CC, Bodurka DC, Weaver CB, et al.: Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005, 13:219–227CrossRefPubMedGoogle Scholar
  5. 48.
    Ettinger DS, Bierman PJ, Bradbury B, et al.: Antiemesis. J Natl Compr Canc Netw 2007, 5:12–33PubMedGoogle Scholar
  6. 49.
    Hesketh PJ, Batchelor D, Golant M, et al.: Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004, 12:543–549PubMedGoogle Scholar
  7. 50.
    Holzner B, Kemmler G, Meraner V, et al.: Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 2003, 97:1564–1572CrossRefPubMedGoogle Scholar
  8. 51.
    Hensley ML, Correa DD, Thaler H, et al.: Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 2006, 102:270–277CrossRefPubMedGoogle Scholar
  9. 52.
    Liavaag AH, Dørum A, Fosså SD, et al.: Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 2007, 25:2049–2056CrossRefPubMedGoogle Scholar
  10. 53.
    Narod SA: Ovarian cancer and HRT in the Million Women Study. Lancet 2007, 369:1667–1668CrossRefPubMedGoogle Scholar
  11. 54.
    Guidozzi F, Daponte A: Estrogen replacement therapy for ovarian carcinoma survivors. Cancer 1999, 86:1013–1018CrossRefPubMedGoogle Scholar
  12. 55.
    Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC: Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 2004, 22:881–889CrossRefPubMedGoogle Scholar
  13. 56.
    Parmar MK, Ledermann JA, Colombo N, et al.: ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099–2106CrossRefPubMedGoogle Scholar
  14. 57.
    Donovan KA, Green PG, Shuster EE, et al.: Treatment Preferences in Recurrent Ovarian Cancer. Gynecol Oncol 2002, 86:200–211CrossRefPubMedGoogle Scholar
  15. 58.
    Mercadante S, Casuccio A, Mangione S: Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage 2007, 33:217–223CrossRefPubMedGoogle Scholar
  16. 59.
    Brooks RA, Herzog TJ: Long-term semi-permanent catheter use for the palliation of malignant ascites. Gynecol Oncol 2006, 101:360–362CrossRefPubMedGoogle Scholar

Copyright information

© Current Science Inc. 2007

Authors and Affiliations

  1. 1.City of Hope Comprehensive Cancer CenterDuarteUSA

Personalised recommendations